Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
dek 2006 · John Wiley & Sons
E-kitab
391
Səhifələr
reportReytinqlər və rəylər doğrulanmır Ətraflı Məlumat
Bu e-kitab haqqında
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Müəllif haqqında
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Bu e-kitabı qiymətləndirin
Fikirlərinizi bizə deyin
Məlumat oxunur
Smartfonlar və planşetlər
Android və iPad/iPhone üçün Google Play Kitablar tətbiqini quraşdırın. Bu hesabınızla avtomatik sinxronlaşır və harada olmağınızdan asılı olmayaraq onlayn və oflayn rejimdə oxumanıza imkan yaradır.
Noutbuklar və kompüterlər
Kompüterinizin veb brauzerini istifadə etməklə Google Play'də alınmış audio kitabları dinləyə bilərsiniz.
eReader'lər və digər cihazlar
Kobo eReaders kimi e-mürəkkəb cihazlarında oxumaq üçün faylı endirməli və onu cihazınıza köçürməlisiniz. Faylları dəstəklənən eReader'lərə köçürmək üçün ətraflı Yardım Mərkəzi təlimatlarını izləyin.
